News

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment.

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04.

Teclistamab plus daratumumab hyaluronidase-fihj has been approved for patients with relapsed/refractory multiple myeloma as part of the CNPV program.

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger age groups with mccRCC.

Abiraterone/prednisone plus olaparib improves survival outcomes vs monotherapy or sequential use in BRCA1/2- or ATM-altered mCRPC.

Explore safety and efficacy findings from KEYNOTE-B15/EV-304, LITESPARK-011, and more from the ASCO Genitourinary Cancers Symposium.

An early but temporary decline in QOL followed by later cognitive effects and pain was seen in patients with RCC receiving adjuvant durvalumab/tremelimumab.

Jacqueline Redeemer, RN, MN, AOCNS, discusses the integration of safe handling practices for oncology nurses and APPs across the oncology continuum.

With the addition of pembrolizumab to standard androgen deprivation therapy and radiation, immune-related adverse events are more likely.

Phase 3 LITESPARK-011 trial results demonstrated PFS and ORR benefits with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC after ICI therapy.

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases.

Neoadjuvant EV plus pembrolizumab significantly improved event-free survival and overall survival vs gemcitabine/cisplatin in the phase 3 KEYNOTE-B15 trial.

ONS is developing a collection of photos of dermatologic toxicities across skin types to address disparities in the care of patients of color with cancer.

Claire Conley, PhD, and Marcelo Sleiman, Jr., discuss the need for protocols in supporting patients’ psychosocial needs.

Patients with PTEN-deficient metastatic hormone-sensitive prostate cancer had improved rPFS with capivasertib plus abiraterone.

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s National Priority Voucher pilot program.

The FDA has approved encorafenib plus cetuximab and fluorouracil-based chemotherapy in patients with BRAF V600E-positive metastatic colorectal cancer.

Of 9 evaluable patients with progressive non–small cell lung cancer (NSCLC) and progressive SCLC, 6 achieved disease control with Olvi-Vec.

What is the role of oncology nurses as artificial intelligence technologies become a clinical reality?

The FDA has approved acalabrutinib plus venetoclax in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

WVU Medicine has begun treating patients in the first clinical trial to explore the use of subcutaneous blinatumomab in patients with CD19-positive MPAL.

FDA fast-tracks trispecific IBI3003, reviews iberdomide combo, and expands Yescarta use.

Emely Alfaro, RN, MSN, CNS, OCN, shares exclusive insights on her cancer-specific research on patients with difficult IV access.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment.

A device delivering tumor treating fields has been approved for concurrent treatment with gemcitabine and nab-paclitaxel for patients with LA-PAC.

Emese Zsiros, MD, PhD, FACOG, discusses managing paclitaxel toxicity and the role of pembrolizumab maintenance in treating platinum-resistant ovarian cancer.

Patients with NRG1 fusion-positive cholangiocarcinoma who received zenocutuzumab had a favorable response rate in the phase 1/2 eNRGy trial.